Supernus Pharmaceuticals is growing revenue at 39% year-over-year and passes the Rule of 40 at a score of 56, but 76% of revenues are concentrated in three drug distributors and the stock is in an oversold technical condition with momentum at 3.2 out of 10 and 11% short interest.
Thesis pillars
- Strong Revenue Growth Rule Of 40→Stable
- Distributor Concentration Risk↑Improving
- Oversold Technicals High Short Interest↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 2, 2026
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Wait for pullback to $39.40. BUY gates pass at $41.08, but concentration risk — Customer: Cencora, Cardinal Health, and McKesson (76.0%) and v7 low-quality RISK_OFF penalty: -0.5 (Q=4.8) argue for a more patient entry. Engine's entry $39.40 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.
Supernus Pharmaceuticals develops and commercializes CNS treatments, with nine FDA-approved products spanning ADHD, Parkinson's disease, postpartum depression, and epilepsy sold primarily in the U.S. Three wholesale distributors—Cencora, Cardinal Health, and... Read more
Wait for pullback to $39.40. BUY gates pass at $41.08, but concentration risk — Customer: Cencora, Cardinal Health, and McKesson (76.0%) and v7 low-quality RISK_OFF penalty: -0.5 (Q=4.8) argue for a more patient entry. Engine's entry $39.40 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Death cross but MACD improving, RSI 45. Earnings today. Wait until post-earnings. Score 6.6/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: aggressive.
About Supernus Pharmaceuticals, Inc.
About Supernus Pharmaceuticals, Inc.
Nine FDA-approved CNS therapies underpin Supernus Pharmaceuticals' revenue base, with Qelbree (ADHD) representing approximately 49% of 2025 total net revenues and GOCOVRI (Parkinson's dyskinesia and OFF episodes) contributing 23%. The company expanded its portfolio through the July 2025 acquisition of Sage Therapeutics for roughly $561 million cash plus contingent value rights tied to ZURZUVAE net sales milestones through 2030. ONAPGO, a subcutaneous apomorphine infusion device for Parkinson's motor fluctuations, received FDA approval in February 2025 and launched in April 2025.
Supernus sells products through pharmaceutical wholesalers and specialty pharmacies in the U.S., with Cencora, Cardinal Health, and McKesson each individually exceeding 15% of total product revenue and together surpassing 76% in 2025. Qelbree is promoted by two dedicated sales forces targeting ADHD specialists, psychiatrists, and primary care physicians; Parkinson's products including GOCOVRI, APOKYN, ONAPGO, and XADAGO are sold by a movement-disorder-focused sales force. ZURZUVAE is co-commercialized with Biogen under a profit-sharing arrangement in the U.S., with Biogen recording product sales and each party sharing operating profits and losses equally. Generic versions of Trokendi XR and Oxtellar XR entered the market in 2023 and 2024 respectively, while settlement agreements permit generic XADAGO entry from December 2027 and generic GOCOVRI from June 2029.
Show full overview
GOCOVRI, which contributed 23% of 2025 net revenues, faces permitted generic entry under settlement beginning June 2029, while XADAGO faces entry from December 2027. The Sage acquisition adds a structured commercial milestone: the CVR agreement requires ZURZUVAE net sales of $250 million in any calendar year through 2027 to unlock the first $1.00-per-share payment, with escalating thresholds through 2030. A supply constraint on ONAPGO disclosed in November 2025 required pausing new patient initiation, with the company reporting progress on securing additional supply in February 2026 and a second supplier expected to begin supplying ONAPGO in 2027.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Supernus Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-29Recent Developments — Supernus Pharmaceuticals, Inc.
Latest news
- NEWS SUPN|Supernus Pharmaceuticals Inc|Price:46.570|Chg%:-1.160 - TradingKey — TradingKey neutral
- NEWS SUPN|Supernus Pharmaceuticals Inc|Price:46.570|Chg%:-1.160 - tradingkey.com — tradingkey.com neutral
- NEWS Supernus Pharmaceuticals earnings: what to look for from SUPN - Yahoo Finance — Yahoo Finance neutral
- NEWS Supernus Pharmaceuticals earnings: what to look for from SUPN - StockStory — StockStory neutral
- NEWS Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl) - Yahoo Finance — Yahoo Finance positive
Generated 2026-10-29T11:53:52Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerCencora, Cardinal Health, and McKesson76%10-K Item 1A: 'Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation...collectively accounted for more than 76% of our total product revenue in 2025'
- MEDIUMProductQelbree49%10-K Item 1A: 'Qelbree®...represented approximately 49%...of our total net revenues for the year ended December 31, 2025'
- LOWProductGOCOVRI23%10-K Item 1A: 'GOCOVRI®...represented approximately...23%...of our total net revenues for the year ended December 31, 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $39.40. BUY gates pass at $41.08, but concentration risk — Customer: Cencora, Cardinal Health, and McKesson (76.0%) and v7 low-quality RISK_OFF penalty: -0.5 (Q=4.8) argue for a more patient entry. Engine's entry $39.40 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Death cross but MACD improving, RSI 45. Earnings today. Wait until post-earnings. Target $51.42 (+25.2%), stop $36.64 (−12.1%), A.R:R 2.9:1. Score 6.6/10, moderate confidence.
Take-profit target: $51.42 (+25.2% upside). Target $51.42 (+25.2%), stop $36.64 (−12.1%), A.R:R 2.9:1. Stop-loss: $36.64.
Concentration risk — Customer: Cencora, Cardinal Health, and McKesson (76.0%); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8); Below 200-MA, MA slope -2.0%/30d (confirmed downtrend).
Supernus Pharmaceuticals, Inc. trades at a P/E of N/A (forward 9.6). TrendMatrix value score: 7.5/10. Verdict: Buy (Wait for Entry).
11 analysts cover SUPN with a consensus score of 4.1/5. Average price target: $61.
What does Supernus Pharmaceuticals, Inc. do?Supernus Pharmaceuticals develops and commercializes CNS treatments, with nine FDA-approved products spanning ADHD,...
Supernus Pharmaceuticals develops and commercializes CNS treatments, with nine FDA-approved products spanning ADHD, Parkinson's disease, postpartum depression, and epilepsy sold primarily in the U.S. Three wholesale distributors—Cencora, Cardinal Health, and McKesson—collectively exceeded 76% of total product revenue in 2025.